New combo therapy targets Hard-to-Treat stomach cancer
NCT ID NCT04522336
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help control gastroesophageal cancer that cannot be removed by surgery. The study includes 16 participants and primarily looks at safety and whether the cancer disappears after treatment. It is a small, early study, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (immunotherapy) plus chemotherapy (docetaxel, fluorouracil, oxaliplatin) and radiation therapy
- What this could lead to
- If successful, this combination could offer a new treatment option for people with gastroesophageal cancer that cannot be surgically removed.
- What could go wrong
- This is a very early phase 1 trial with only 16 participants, so results may not apply broadly. Side effects from the drug combination and radiation could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug combo targets Hard-to-Treat GI cancers
- New drug cocktail aims to fight Hard-to-Treat stomach cancers
- Experimental combo targets Hard-to-Treat esophageal cancer
- New study tracks physical decline during cancer treatment
- New drug cocktail targets Hard-to-Treat stomach cancer
- Custom-Made cancer vaccine shows promise in advanced tumors